Immuron Ltd has released a press release.
NASH clinical trial presentation & continued revenue growth
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- US DoD Report Travelan Protects Against Shigella in Primates
- Immuron Reports Record Revenue
- US Department of Defense Research Collaboration Moves Ahead
- European Patent Gramted for Nash Treatment
- Immuron Announces Board Appointment
Later from Immuron
- IMC Appoints Experienced US Based Biotech Executive as CEO
- Immuron Receives $1.19M R&D Tax Concession Refund
- Form F-3
- Travelan FY19 Update and Expansion into North America
- Company Update on CDI Clinical Trial and New Strategic Focus
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron